Foghorn Therapeutics Inc. Common Stock

Step Pharma appoints Neil J. Gallagher, MD, PhD as Non-Executive Director to strengthen its board as it advances dencatistat, a first-in-class CTPS1 inhibitor, across three clinical programmes for essential thrombocythaemia, lymphoma, and solid tumours. Gallagher brings over 25 years of clinical development experience from senior roles at major p...

Foghorn Therapeutics announced it will present multiple oral and poster presentations at the 2026 AACR Annual Meeting in San Diego. The company will showcase new preclinical data for FHD-909 (LY4050784), a selective SMARCA2 inhibitor developed with Eli Lilly for SMARCA4-mutant cancers, including potential combination opportunities with anti-PD-1 ...

The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep...

Foghorn Therapeutics raised $50 million in equity financing from BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund. The company reported progress on its Phase 1 trial of FHD-909 (partnered with Eli Lilly) for SMARCA4-mutant cancers, with selective CBP and EP300 degrader programs advancing toward IND filings in 202...

4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.